Clinical pharmacology: Principles of analgesic drug management

Clinical Pain Management: Cancer Pain, Second Edition

Volumn , Issue , 2008, Pages 103-122

  Schug, Stephan A ^a   Auret, Kirsten ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84866989216     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (192)

1. Woodruff R. Cancer pain, 2nd edn. Heidelberg, Victoria: Asperula, 1999
2. Cassell E. The nature of suffering and the goals of medicine. New England Journal of Medicine. 1982; 306: 639-45
3. Saunders C. The management of terminal illness. London: Edward Arnold, 1967
4. Skaer TL. Management of pain in the cancer patient. Clinical Therapeutics. 1993; 15: 638-49
5. Hammack J, Loprinzi C. Use of orally administered opioids for cancer-related pain [review]. Mayo Clinic Proceedings. 1994; 69: 384-90
6. Portenoy R. Pharmacologic management of cancer pain. Seminars in Oncology. 1995; 22: 112-20
7. Meldrum M. The ladder and the clock: cancer pain and public policy at the end of the twentieth century. Journal of Pain and Symptom Management. 2005; 29: 41-54
8. World Health Organization. Cancer pain management. WHO Technical Report Series. Geneva: WHO, 1986
9. World Health Organization. Cancer pain relief. With a guide to opioid availability, 2nd edn. Geneva: WHO, 1996
10. Hillier R. Control of pain in terminal cancer. British Medical Bulletin. 1990; 46: 279-91
11. Blanchard CG, Ruckdeschel JC. Psychosocial aspects of cancer in adults: implications for teaching medical students. Journal of Cancer Education. 1986; 1: 237-48
12. Gadow S. An ethical case for patient self-determination. Seminars in Oncology Nursing. 1989; 5: 99-101
13. Levenson BS. A multidimensional approach to the treatment of pain in the oncology patient. Frontiers of Radiation Therapy and Oncology. 1980; 15: 138-41
14. Grond S, Zech D, Lynch J et al. Validation of the World Health Organization guidelines for pain relief in head and neck cancer. A prospective study. Annals of Otology, Rhinology, and Laryngology. 1993; 102: 342-8
15. Donato V, Montagna A, Musio D, Cellini N. Radiotherapy in the symptomatic treatment of the oncological patients. Anticancer Research. 1999; 19: 3375-82
16. Ramirez AJ, Towlson KE, Leaning MS et al. Do patients with advanced breast cancer benefit from chemotherapy? British Journal of Cancer. 1998; 78: 1488-94
17. Fourneau I, Broos P. Pathologic fractures due to metastatic disease. A retrospective study of 160 surgically treated fractures. Acta Chirurgica Belgica. 1998; 98: 255-60
18. Weigel B, Maghsudi M, Neumann C et al. Surgical management of symptomatic spinal metastases. Postoperative outcome and quality of life. Spine. 1999; 24: 2240-6
19. Collett BJ. Opioid tolerance: the clinical perspective. British Journal of Anaesthesia. 1998; 81: 58-68
20. Portenoy RK. Opioid tolerance and responsiveness: research findings and clinical observations. In: Gebhart GF, Hammond DL, Jensen TS (eds). Proceedings of the 7th World Congress on Pain, Progress in Pain Research and Management. Seattle: IASP Press, 1994: 595-619
21. Stevens CW, Yaksh TL. Studies of morphine and D-ala2-Dleu5-enkephalin (DADLE) cross-tolerance after continuous intrathecal infusion in the rat. Anesthesiology. 1992; 76: 596-603
22. Schug SA, Zech D, Grond S et al. A long-term survey of morphine in cancer pain patients. Journal of Pain and Symptom Management. 1992; 7: 259-66
23. Brescia FJ, Portenoy RK, Ryan M et al. Pain, opioid use, and survival in hospitalized patients with advanced cancer. Journal of Clinical Oncology. 1992; 10: 149-55
24. Marinangeli F, Ciccozzi A, Leonardis M et al. Use of strong opioids in advanced cancer pain: a randomized trial. Journal of Pain and Symptom Management. 2004; 27: 409-16
25. Portenoy RK. Tolerance to opioid analgesics: Clinical aspects. Cancer Surveys. 1994; 21: 49-65
26. Kanner RM, Foley KM. Patterns of narcotic drug use in a cancer pain clinic. Annals of the New York Academy of Sciences. 1981; 362: 161-72
27. Foley KM. Controversies in cancer pain. Medical perspectives. Cancer. 1989; 63: 2257-65
28. Mercadante S. Opioid rotation for cancer pain: rationale and clinical aspects. Cancer. 1999; 86: 1856-66
29. Quigley C. Opioid switching to improve pain relief and drug tolerability. Cochrane Dataase of Systematic Reviews. 2004; CD004847
30. Miller RR, Olson HG, Amsterdam EA, Mason DT. Propranolol-withdrawal rebound phenomenon. Exacerbation of coronary events after abrupt cessation of antianginal therapy. New England Journal of Medicine. 1975; 293: 416-8
31. Neusy AJ, Lowenstein J. Blood pressure and blood pressure variability following withdrawal of propranolol and clonidine. Journal of Clinical Pharmacology. 1989; 29: 18-24
32. Warner CH, Bobo W, Warner C et al. Antidepressant discontinuation syndrome. American Family Physician. 2006; 74: 449-56
33. Kreek MJ, Koob GF. Drug dependence: stress and dysregulation of brain reward pathways. Drug and Alcohol Dependence. 1998; 51: 23-47
34. Manfredi PL, Ribeiro S, Chandler SW, Payne R. Inappropriate use of naloxone in cancer patients with pain. Journal of Pain and Symptom Management. 1996; 11: 131-4
35. Hanks GWC, Cherny N. Opioid analgesic therapy. In: Doyle D (ed.). Oxford textbook of palliative medicine, 2nd edn. Oxford: Oxford University Press, 1998: 331-54
36. Savage SR. Assessment for addiction in pain-treatment settings. Clinical Journal of Pain. 2002; 18: S28-38
37. Anonymous. Diagnostic and Statistical Manual of Mental Disorders, Text Revision (DSM-IV-TRs), 4th edn. Arlington: American Psychiatric Association, 2000: 992
38. Porter J, Jick H. Addiction rare in patients treated with narcotics. New England Journal of Medicine. 1980; 302: 123
39. Chapman CR, Hill HF. Prolonged morphine selfadministration and addiction liability. Evaluation of two theories in a bone marrow transplant unit. Cancer. 1989; 63: 1636-44
40. Sun WZ, Chen TL, Fan SZ et al. Can cancer pain attenuate the physical dependence on chronic long-term morphine treatment? Journal of the Formosan Medical Association. 1992; 91: 513-20
41. Joranson D. Availability of opioids for cancer pain: recent trends, assessment of system barriers, new World Health Organization guidelines, and the risk of diversion. Journal of Pain and Symptom Management. 1993; 8: 353-60
42. Joranson DE, Ryan KM, Gilson AM, Dahl JL. Trends in medical use and abuse of opioid analgesics. Journal of the American Medical Association. 2000; 283: 1710-4
43. Costa e Silva JA. Evidence-based analysis of the worldwide abuse of licit and illicit drugs. Human Psychopharmacology. 2002; 17: 131-40
44. Weissman DE, Haddox JD. Opioid pseudoaddiction an iatrogenic syndrome. Pain. 1989; 36: 363-6
45. Secor JW, Schenker S. Drug metabolism in patients with liver disease. Advances in Internal Medicine. 1987; 32: 379-405
46. Sawe J. High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment. Clinical Pharmacokinetics. 1986; 11: 87-106
47. Neal EA, Meffin PJ, Gregory PB, Blaschke TF. Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis. Gastroenterology. 1979; 77: 96-102
48. Schug SA, Morgan J. Treatment of cancer pain: special considerations in patients with renal disease. American Journal of Cancer. 2004; 3: 247-56
49. Fillastre JP, Singlas E. Pharmacokinetics of newer drugs in patients with renal impairment. Clinical Pharmacokinetics. 1991; 20: 293-310
50. Lam YW, Banerji S, Hatfield C, Talbert RL. Principles of drug administration in renal insufficiency. Clinical Pharmacokinetics. 1997; 32: 30-57
51. Touchette MA, Slaughter RL. The effect of renal failure on hepatic drug clearance. DICP. 1991; 25: 1214-24
52. Reetze-Bonorden P, Bohler J, Keller E. Drug dosage in patients during continuous renal replacement therapy. Clinical Pharmacokinetics. 1993; 24: 362-79
53. World Health Organization. Cancer pain relief and palliative care, 2nd edn. Geneva: WHO, 1996: 63
54. Takeda F. Results of field testing in Japan of the WHO Draft Interim Guidelines on relief of cancer pain. Pain Clinic. 1986; 1: 83-9
55. Ventafridda V, Tamburini M, Caraceni A et al. A validation study of the WHO method for cancer pain relief. Cancer. 1987; 59: 850-6
56. Schug SA, Zech D, Doerr U. Cancer pain management according to WHO Analgesic Guidelines. Journal of Pain and Symptom Management. 1990; 5: 27-32
57. Zech D, Grond S, Lynch J et al. Validation of the World Health Organization Guidelines for cancer pain relief: a 10-year prospective study. Pain. 1995; 63: 65-76
58. Stjernsward J, Colleau S, Ventafridda V. The World Health Organization cancer pain and palliative car program. Past, present and future. Journal of Pain and Symptom Management. 1996; 12: 65-72
59. Walsh TD. Oral morphine in chronic cancer pain. Pain. 1984; 18: 1-11
60. Hanks GW, Conno F, Cherny N et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. British Journal of Cancer. 2001; 84: 587-93
61. Mercadante SG. When oral morphine fails in cancer pain: the role of the alternative routes. American Journal of Hospice and Palliative Care. 1998; 15: 333-42
62. Glare P. Problems with opiates in cancer pain: parenteral opioids. Supportive Care in Care Cancer. 1997; 5: 445-50
63. Coyle N, Adelhardt J, Foley KM, Portenoy RK. Character of terminal illness in the advanced cancer patient: pain and other symptoms during the last four weeks of life. Journal of Pain and Symptom Management. 1990; 5: 83-93
64. Cherny NJ, Chang V, Frager G et al. Opioid pharmacotherapy in the management of cancer pain: a survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration. Cancer. 1995; 76: 1283-93
65. Skaer TL. Transdermal opioids for cancer pain. Health and Quality of Life Outcomes. 2006; 4: 24
66. Chelly JE. An iontophoretic, fentanyl HCl patientcontrolled transdermal system for acute postoperative pain management. Expert Opinion on Pharmacotherapy. 2005; 6: 1205-14
67. DeConno F, Ripamonti C, Saita L et al. Role of rectal route in treating cancer pain: a randomised crossover clinical trial of oral versus rectal morphine administration in opioid-naive cancer patients with pain. Journal of Clinical Oncology. 1995; 13: 1004-08
68. Moulin DE, Johnson NG, Murray-Parsons N et al. Subcutaneous narcotic infusions for cancer pain: treatment outcome and guidelines for use. Canadian Medical Association Journal. 1992; 146: 891-7
69. Ripamonti C, Bruera E. Rectal, buccal, and sublingual narcotics for the management of cancer pain. Journal of Palliative Care. 1991; 7: 30-5
70. Breda M, Bianchi M, Ripamonti C et al. Plasma morphine and morphine-6-glucuronide patterns in cancer patients after oral, subcutaneous, sublabial and rectal short-term administration. International Journal of Clinical Pharmacology Research. 1991; 11: 93-7
71. Wilkinson TJ, Robinson BA, Begg EJ et al. Pharmacokinetics and efficacy of rectal versus oral sustained-release morphine in cancer patients. Cancer Chemotherapy and Pharmacology. 1992; 31: 251-4
72. Nelson KA, Glare PA, Walsh D, Groh ES. A prospective, within-patient, crossover study of continuous intravenous and subcutaneous morphine for chronic cancer pain. Journal of Pain and Symptom Management. 1997; 13: 262-7
73. Glare PA, Walsh TD. Clinical pharmacokinetics of morphine. Therapeutic Drug Monitoring. 1991; 13: 1-23
74. Hanks GW, de Conno F, Ripamonti V et al. Morphine in cancer pain: modes of administration. British Medical Journal. 1996; 312: 823-6
75. Gilbar PJ. A guide to enternal drug administration in palliative care. Journal of Pain and Symptom Management. 1999; 17: 197-207
76. Weinberg DS, Inturrisi CE, Reidenberg B et al. Sublingual absorption of selected opioid analgesics. Clinical Pharmacology and Therapeutics. 1988; 44: 335-42
77. Davis MP. Buprenorphine in cancer pain. Supportive Care in Cancer. 2005; 13: 878-87
78. Zeppetella G, Ribeiro MD. Opioids for the management of breakthrough (episodic) pain in cancer patients. Cochrane Database of Systematic Reviews. 2006; CD004311
79. Portenoy RK. Managing cancer pain poorly responsive to systemic opioid therapy. Oncology (Williston Park). 1999; 13: 25-9
80. Grond S, Zech D, Schug SA et al. Validation of the World Health Organization guidelines for cancer pain relief during the last days and hours of life. Journal of Pain and Symptom Management. 1991; 6: 411-22
81. Schug SA, Dunlop R, Zech D. Pharmacological management of cancer pain. Drugs. 1992; 43: 44-53
82. Moote C. The prevention of postoperative pain. Canadian Journal of Anaesthesia. 1994; 41: 527-33
83. Tuttle C. Drug management of pain in cancer patients. Canadian Medical Association Journal. 1985; 132: 121-34
84. Smith K, Broomhead A, Kerr R et al. Comparison of a oncea-day sustained-release morphine formulation with standard oral morphine treatment for cancer pain. Journal of Pain and Symptom Management. 1997; 14: 63-73
85. Arkinstall WW, Goughnour BR, White JA, Stewart JH. Control of severe pain with sustained-release morphine tablets voral morphine solution. Canadian Medical Association Journal. 1989; 140: 653-7, 61
86. Goughnour BR, Arkinstall WW, Stewart JH. Analgesic response to single and multiple doses of controlledrelease morphine tablets and morphine oral solution in cancer patients. Cancer. 1989; 63: 2294-7
87. McCormack J, Warriner C, Levine M, Glick N. A Comparison of regularly dosed oral morphine and on-demand intramuscular morphine in the treatment of postsurgical pain. Canadian Journal of Anaesthesiology. 1993; 40: 819-24
88. Foley K. The treatment of cancer pain. The New England Journal of Medicine. 1985; 313: 84-95
89. Grond S, Zech D, Schug SA et al. The importance of nonopioid analgesics for cancer pain relief according to the guidelines of the World Health Organization. International Journal of Clinical Pharmacology Research. 1991; 11: 253-60
90. McNicol E, Strassels SA, Goudas L et al. NSAIDS or paracetamol, alone or combined with opioids, for cancer pain. Cochrane Database of Systematic Reviews. 2005; CD005180
91. Stockler M, Vardy J, Pillai A, Warr D. Acetaminophen (paracetamol) improves pain and well-being in people with advanced cancer already receiving a strong opioid regimen: a randomized, double-blind, placebo-controlled cross-over trial. Journal of Clinical Oncology. 2004; 22: 3389-94
92. Rodriguez M, Barutell C, Rull M et al. Efficacy and tolerance of oral dipyrone versus oral morphine for cancer pain. European Journal of Cancer. 1994; 5: 584-7
93. Ventafridda V, De Conno F, Panerai AE et al. Non-steroidal anti-inflammatory drugs as the first step in cancer pain therapy: double-blind, within-patient study comparing nine drugs. Journal of International Medical Research. 1990; 18: 21-9
94. Jenkins CA, Bruera E. Nonsteroidal anti-inflammatory drugs as adjuvant analgesics in cancer patients. Palliative Medicine. 1999; 13: 183-96
95. Stambaugh J, Drew J. The combination of ibuprofen and oxycodone/acetaminophen in the management of chronic cancer pain. Clinical Pharmacology and Therapeutics. 1988; 44: 665-9
96. Weingart W, Sorkness C, Earhart R. Analgesia with oral narcotics and added ibuprofen in cancer patients. Clinical Pharmacy. 1985; 4: 53-8
97. Mercadante S, Sapio M, Caligara M et al. Opioid sparing effect of Diclofenac in cancer pain. Journal of Pain and Symptom Management. 1997; 14: 15-20
98. Dhaliwal HS, Sloan P, Arkinstall WW et al. Randomized evaluation of controlled-release codeine and placebo in chronic cancer pain. Journal of Pain and Symptom Management. 1995; 10: 612-23
99. Jochimsen PR, Noyes Jr. R. Appraisal of codeine as an analgesic in older patients. Journal of the American Geriatrics Society. 1978; 26: 521-3
100. Mercadante S, Salvaggio L, Dardanoni G et al. Dextropropoxyphene versus morphine in opioid-naive cancer patients with pain. Journal of Pain and Symptom Management. 1998; 15: 76-81
101. Li Wan Po A, Zhang WY. Systematic overview of coproxamol to assess analgesic effects of addition of dextropropoxyphene to paracetamol. British Medical Journal. 1997; 315: 1565-71
102. Jurna I, Komen W, Baldauf J, Fleischer W. Analgesia by dihydrocodeine is not due to formation of dihydromorphine: evidence from nociceptive activity in rat thalamus. Journal of Pharmacology and Experimental Therapeutics. 1997; 281: 1164-70
103. Klepstad P, Kaasa S, Cherny N et al. Pain and pain treatments in European palliative care units. A cross sectional survey from the European Association for Palliative Care Research Network. Palliative Medicine. 2005; 19: 477-84
104. Petzke F, Radbruch L, Sabatowski R et al. Slow-release tramadol for treatment of chronic malignant pain an open multicenter trial. Supportive Care in Cancer. 2001; 9: 48-54
105. Wilder-Smith CH, Schimke J, Osterwalder B, Senn HJ. Oral tramadol, a mu-opioid agonist and monoamine reuptakeblocker, and morphine for strong cancer-related pain. Annals of Oncology. 1994; 5: 141-6
106. Grond S, Zech D, Lynch J et al. Tramadol A weak opioid for relief of cancer pain. Pain Clinic. 1992; 5: 241-7
107. Eisenberg E, Berkey C, Carr D et al. Efficacy and safety of non-steroidal antiinflammatory drugs for cancer pain: a meta-analysis. Journal of Clinical Oncology. 1994; 12: 2756-65
108. Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. Canadian Medical Association Journal. 2006; 174: 1589-94
109. Freynhagen R, Zenz M, Strumpf M. WHO step II-clinical reality or a didactic instrument? Schmerz. 1994; 8: 210-15
110. Grond S, Meuser T. Weak opioids An educational substitute for morphine? Current Opinion in Anaesthesiology. 1998; 11: 559-65
111. Zenz M, Willweber-Strumpf A. Opiophobia and cancer pain in Europe. Lancet. 1993; 341: 1075-6
112. Morgan JP. American opiophobia: Customary underutilization of opioid analgesics. Advances in Alcohol and Substance Abuse. 1985; 5: 163-73
113. Weinstein SM, Laux LF, Thornby JI et al. Medical students’ attitudes toward pain and the use of opioid analgesics: implications for changing medical school curriculum. Southern Medical Journal. 2000; 93: 472-8
114. Grond S, Radbruch L, Meuser T et al. High-dose tramadol in comparison to low-dose morphine for cancer pain relief. Journal of Pain and Symptom Management. 1999; 18: 174-9
115. Raffa RB, Friderichs E, Reimann W et al. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an ‘atypical’ opioid analgesic. Journal of Pharmacology and Experimental Therapeutics. 1992; 260: 275-85
116. Duhmke RM, Cornblath DD, Hollingshead JR. Tramadol for neuropathic pain. Cochrane Database of Systematic Reviews. 2004; CD003726
117. Radbruch L, Grond S, Lehmann KA. A risk-benefit assessment of tramadol in the management of pain. Drug Safety. 1996; 15: 8-29
118. Sacerdote P, Bianchi M, Gaspani L et al. The effects of tramadol and morphine on immune responses and pain after surgery in cancer patients. Anesthesia and Analgesia. 2000; 90: 1411-14
119. Klepstad P, Kaasa S, Borchgrevink PC. Start of oral morphine to cancer patients: effective serum morphine concentrations and contribution from morphine-6glucuronide to the analgesia produced by morphine. European Journal of Clinical Pharmacology. 2000; 55: 713-19
120. Wiffen PJ, Edwards JE, Barden J, McQuay HJ. Oral morphine for cancer pain. Cochrane Database of Systematic Reviews. 2003; CD003868
121. World Health Organization. Essential Medicines. WHO Model List. Last updated: revised March 2005; cited 03 Oct, 2006. Available from: www.who.int/medicines/publications/essentialmedicines/en/
122. Gourlay GK, Cherry DA, Cousins MJ. A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer. Pain. 1986; 25: 297-312
123. Nicholson AB. Methadone for cancer pain. Cochrane Database of Systematic Reviews. 2004; CD003971
124. Bruera E, Palmer JL, Bosnjak S et al. Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. Journal of Clinical Oncology. 2004; 22: 185-92
125. Reid CM, Martin RM, Sterne JA et al. Oxycodone for cancer-related pain: meta-analysis of randomized controlled trials. Archives of Internal Medicine. 2006; 166: 837-43
126. Murray A, Hagen NA. Hydromorphone. Journal of Pain and Symptom Management. 2005; 29: S57-66
127. Mystakidou K, Parpa E, Tsilika E et al. Pain management of cancer patients with transdermal fentanyl: a study of 1828 step I, II, & III transfers. Journal of Pain. 2004; 5: 119-32
128. Sittl R. Transdermal buprenorphine in cancer pain and palliative care. Palliative Medicine. 2006; 20: s25-30
129. Latta KS, Ginsberg B, Barkin RL. Meperidine: a critical review. American Journal of Therapeutics. 2002; 9: 53-68
130. Venegas G, Ripamonti C, Sbanotto A, Conno FD. Side effects of morphine administration in cancer pain. Cancer Nursing. 1998; 21: 289-97
131. Walsh TD. Prevention of opioid side effects. Journal of Pain and Symptom Management. 1990; 5: 362-7
132. Hanks GW, Twycross RG. Pain, the physiological antagonist of opioid analgesics. Lancet. 1984; 1: 1477-8
133. Ravenscroft P, Schneider J. Bedside perspectives on the use of opioids: transferring results of clinical research into practice. Clinical and Experimental Pharmacology and Physiology. 2000; 27: 529-32
134. Quevedo F, Walsh D. Morphine-induced ventilatory failure after spinal cord compression. Journal of Pain and Symptom Management. 1999; 18: 140-2
135. Curtis EB, Walsh TD. Prescribing practices of a palliative care service. Journal of Pain and Symptom Management. 1993; 8: 312-6
136. Lazarus H, Fitzmartin R, Goldenheim P. A multiinvestigator clinical evaluation of oral controlled-release morphine (MS Contin tablets) administered to cancer patients. Hospice Journal. 1990; 6: 1-15.
137. Mancini I, Bruera E. Constipation in advanced cancer patients. Supportive Care in Cancer. 1998; 6: 356-64
138. Bruera E, Macmillan K, Hanson J, MacDonald RN. The cognitive effects of the administration of narcotic analgesics in patients with cancer pain. Pain. 1989; 39: 13-6
139. de Stoutz ND, Bruera E, Suarez-Almazor M. Opioid rotation for toxicity reduction in terminal cancer patients. Journal of Pain and Symptom Management. 1995; 10: 378-84
140. Vainio A, Ollila J, Matikainen E et al. Driving ability in cancer patients receiving long-term morphine analgesia. Lancet. 1995; 346: 667-70
141. Banning A, Sjogren P. Cerebral effects of long-term oral opioids in cancer patients measured by continuous reaction time. Clinical Journal of Pain. 1990; 6: 91-5
142. Banning A, Sjogren P, Kaiser F. Reaction time in cancer patients receiving peripherally acting analgesics alone or in combination with opioids. Acta Anaesthesiologica Scandinavica. 1992; 36: 480-2
143. Schug S, Zech D, Grond S et al. A long-term survey of morphine in cancer pain patients. Journal of Pain and Symptom Management. 1992; 7: 259-66
144. Wiffen P, Collins S, McQuay H et al. Anticonvulsant drugs for acute and chronic pain. Cochrane Database of Systematic Reviews. 2005; CD001133
145. Challapalli V, Tremont-Lukats I, McNicol E et al. Systemic administration of local anesthetic agents to relieve neuropathic pain. Cochrane Database of Systematic Reviews. 2005; CD003345
146. Saarto T, Wiffen P. Antidepressants for neuropathic pain. Cochrane Database of Systematic Reviews. 2005; CD005454
147. Body JJ. Bisphosphonates for malignancy-related bone disease: current status, future developments. Supportive Care in Cancer. 2006; 14: 408-18
148. Hanks GW, Trueman T, Twycross RG. Corticosteroids in terminal cancer — a prospective analysis of current practice. Postgraduate Medical Journal. 1983; 59: 702-6
149. Kopf A. [Co-analgesics in the treatment of chronic pain]. Therapeutische Umschau. 1999; 56: 441-5
150. Mancini I, Body JJ. [Treatment of cancer pain: the role of co-analgesics]. Revue Medicale de Bruxelles. 1998; 19: A319-22
151. Rouveix B, Bauwens MC, Giroud JP. [Treatment of different types of pain]. Bulletin de l’Academie Nationale Medecine. 1999; 183: 889-901
152. Bruera E, Pereira J, Watanabe S et al. Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer. 1996; 78: 852-7
153. Sjogren P, Jensen NH, Jensen TS. Disappearance of morphine-induced hyperalgesia after discontinuing or substituting morphine with other opioid agonists. Pain. 1994; 59: 313-6
154. Smith MT. Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites. Clinical and Experimental Pharmacology and Physiology. 2000; 27: 524-8
155. Caraceni A, Martini C, Zecca E et al. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliative Medicine. 2004; 18: 177-83
156. Simmonds MA. Management of breakthrough pain due to cancer. Oncology (Huntingt). 1999; 13: 1103-08; discussion 10, 13-14
157. Patt RB, Ellison NM. Breakthrough pain in cancer patients: characteristics, prevalence, and treatment. Oncology (Huntingt). 1998; 12: 1035-46; discussion 49-52
158. Rogers AG. How to manage incident pain. Journal of Pain and Symptom Management. 1987; 2: 99
159. McQuay HJ, Jadad AR. Incident pain. Cancer Surveys. 1994; 21: 17-24
160. Portenoy R, Hagen N. Breakthrough pain: definition, prevalence and characteristics. Pain. 1990; 41: 273-81
161. International Association for the Study of Pain. Pain terms. Pain. 1979; 6: 249
162. Boisvert M, Cohen SR. Opioid use in advanced malignant disease: why do different centers use vastly different doses? A plea for standardized reporting. Journal of Pain and Symptom Management. 1995; 10: 632-8
163. Twycross R. Medical treatment of cancer pain. Bulletin on Cancer. 1980; 67: 209-16
164. Klepstad P, Borchgrevink PC, Kaasa S. Effects on cancer patients’ health-related quality of life after the start of morphine therapy. Journal of Pain and Symptom Management. 2000; 20: 19-26
165. Brooks I, De Jager R, Blumenreich M et al. Principles of cancer pain management. Use of long-acting oral morphine. Journal of Family Practice. 1989; 28: 275-80
166. Cleeland CS, Gonin R, Hatfield AK et al. Pain and its treatment in outpatients with metastatic cancer. New England Journal of Medicine. 1994; 330: 592-6
167. Bonica JJ. The Management of Pain, 2nd edn. Vol. 1. Philadelphia: Lea and Febiger Press, 1990
168. Sullivan M, Rapp S, Fitzgibbon D, Chapman CR. Pain and the choice to hasten death in patients with painful metastatic cancer. Journal of Palliative Care. 1997; 13: 18-28
169. Marks RM, Sachar EJ. Undertreatment of medical inpatients with narcotic analgesics. Annals of Internal Medicine. 1973; 78: 173-81
170. Janjan N, Payne R, Gillis T et al. Presenting symptoms in patients referred to a multidisciplinary clinic for bone metastases. Journal of Pain and Symptom Management. 1998; 16: 171-8
171. Lander J. Fallacies and phobias about addiction and pain. British Journal of Addiction. 1990; 85: 803-9
172. Kaasalainen V, Vainio A, Ali-Melkkila T. Developments in the treatment of cancer pain in Finland: the third nationwide survey. Pain. 1997; 70: 175-83
173. Mercadante S, Salvaggio L. Cancer pain knowledge in Southern Italy: data from a postgraduate refresher course. Journal of Pain and Symptom Management. 1996; 11: 108-15
174. McQuay HJ. Opioids in pain management. Lancet. 1999; 353: 2229-32
175. Joranson DE, Gilson AM. Pharmacists’ knowledge of and attitudes toward opioid pain medications in relation to federal and state policies. Journal of the American Pharmaceutical Association. 2001; 41: 213-20
176. Edwards HE, Nash RE, Najman JM et al. Determinants of nurses’ intention to administer opioids for pain relief. Nursing and Health Sciences. 2001; 3: 149-59
177. Gaylin W, Kass LR, Pellegrino ED, Siegler M. ‘Doctors must not kill’. Journal of the American Medical Association. 1988; 259: 2139-40
178. Wall PD. The generation of yet another myth on the use of narcotics. Pain. 1997; 73: 121-2
179. Cleeland CS, Gonin R, Baez L et al. Pain and treatment of pain in minority patients with cancer. The Eastern Cooperative Oncology Group Minority Outpatient Pain Study. Annals of Internal Medicine. 1997; 127: 813-6
180. Saxena A, Mendoza T, Cleeland CS. The assessment of cancer pain in North India: The validation of the hindi brief pain inventory BPI-H. Journal of Pain and Symptom Management. 1999; 17: 27-41
181. Uki J, Mendoza T, Cleeland CS et al. A brief cancer pain assessment tool in Japanese: the utility of the Japanese Brief Pain Inventory BPI-J. Journal of Pain and Symptom Management. 1998; 16: 364-73
182. United Nations. Single Convention on Narcotic Drugs. United Nations, Treaty Series. 1961; 520: 151
183. Jadad A, Browman G. The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation. Journal of the American Medical Association. 1995; 274: 1870-3
184. Lichter I, Hunt E. The last 48 hours of life. Journal of Palliative Care. 1990; 6: 7-15
185. Rozans M, Dreisbach A, Lertora J, Kahn M. Palliative uses of methylphenidate in patients with cancer: a review. Journal of Clinical Oncology. 2002; 20: 335-9
186. Dalal S, Melzack R. Potentiation of opioid analgesia by psychostimulant drugs: a review. Journal of Pain and Symptom Management. 1998; 16: 245-53
187. Thomsen AB, Becker N, Eriksen J. Opioid rotation in chronic non-malignant pain patients. A retrospective study. Acta Anaesthesiologica Scandinavica. 1999; 43: 918-23
188. Wang JK. Intrathecal morphine for intractable pain secondary to cancer of pelvic organs. Pain. 1985; 21: 99-102
189. Lynch J, Zech D, Grond S. The role of intrathecal neurolysis in the treatment of cancer-related perianal and perineal pain. Palliative Medicine. 1992; 6: 140-5
190. Field MJ, Lohr KN. Clinical practice guidelines: directions for a new program. Institute of Medicine. Washington DC: National Academy Press, 1990
191. Cleeland CS, Portenoy RK, Rue M et al. Does an oral analgesic protocol improve pain control for patients with cancer? An intergroup study coordinated by the Eastern Cooperative Oncology Group. Annals of Oncology. 2005; 16: 972-80
192. Du Pen SL, Du Pen AR, Polissar N et al. Implementing guidelines for cancer pain management: results of a randomized controlled clinical trial. Journal of Clinical Oncology. 1999; 17: 361-70.